Exhibit 99.1

               CAVIT SCIENCES, INC. ANNOUNCES FINANCING AGREEMENTS

     DELRAY BEACH, FL, NOVEMBER 30, 2007--CAVIT SCIENCES, INC. ("Cavit") (OTCBB:
CVIT)  announced that it has disclosed in a Form 8-K, that on November 29, 2007,
it executed two Common Stock Purchase Agreements.

As part of the financing, Cavit has begun to receive funding of $500,000 through
the sale of its  common  stock to Vision  International  Enterprises,  S.A.  and
Isthmus Investments Management S.A. ("Investors"). In addition, Cavit will issue
the Investors common stock purchase  warrants to purchase  additional  shares at
exercise  prices ranging from $.40 to $3.00 per share.  The Agreements and terms
are available on Cavit's Form 8-K.

With the execution of Cavit's business plan and future operations ensured,  this
financing allows the Company to initiate the successful commercialization of its
products and aggressively proceed forward.. Product information and updates will
soon be available on Cavit's website.

Cavit Sciences,  Inc. ("Cavit") is a biotechnology company engaged in developing
treatments   and  prevention  for  cancer,   viral   infections,   opportunistic
infections,  related  diseases  and the immune  system.  Additional  information
regarding  our drug  development,  supplement  line and Company  information  is
available on the Company's website at: www.cavitsciences.com

Statements  contained herein that are not historical fact may be forward-looking
statements  within the meaning of Section 27A of the  Securities Act of 1933 and
Section  21E of the  Securities  Exchange  Act of 1934,  that are  subject  to a
variety of risks and uncertainties. There are a number of important factors that
could  cause  actual  results  to differ  materially  from  those  projected  or
suggested  in any  forward-looking  statements  made  by  Cavit.  These  factors
include,  but are not limited to: (i) the ability of Cavit to successfully raise
financing,  (ii)  the  ability  of  Cavit  to  finalize  its  manufacturing  and
distribution  facilities,  and  (iii)  the  ability  of  Cavit  to  successfully
commercialize  its products in certain  markets.  Additional  factors that would
cause actual results to differ  materially  from those projected or suggested in
any  forward-looking  statements  are  contained  in  Cavit's  filings  with the
Securities and Exchange Commission,  including those factors discussed under the
caption "Risk  Factors" for Cavit on Form 10K-SB filed on April 12, 2007 and its
subsequently filed Forms 10-QSB.

CONTACT:
Colm J. King, CEO (561) 278-7856
Cavit Sciences, Inc. www.cavitsciences.com